Scientists have recently explained the experience of spirituality, transcendence, and religiosity. The problem was identified to be 5-hydroxytryptamine re-uptake rates within the Substantia Nigra. The condition, initially thought to affect 48% of the population, is due to a mutation in the gene SLC6A4.
Pfizer have subsequently developed a drug treatment, and human trials of Sartrezine have begun.
Initial results have proven positive. People who reported feelings of interconnectedness with the universe and/or a faith in God, experienced a marked reduction in symptoms within 4 days of treatment. Placebo patients reported similar effects, but at a significantly lower rate.
Many patients who actively participated in organised religious ritual however, continued to display these behaviours, regardless of blood serum levels of Satrezine. A faith in God it has been proposed, has no clear correlation to religious behaviour. In some cases, a marked increase in these behaviours were noted, with a concomitant shift towards Conservative political bias.
Some serious side effects to Sartrezine have been reported. Relationship difficulties, emotional bluntness and irresponsible behaviour have been noted in 25% of patients.
The National Institute for Clinical Excellence is investigating its effectiveness for use in the NHS.